These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9158515)

  • 1. Free and total prostate-specific antigen in a screened population.
    Bangma CH; Kranse R; Blijenberg BG; Schröder FH
    Br J Urol; 1997 May; 79(5):756-62. PubMed ID: 9158515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men.
    Bangma CH; Kranse R; Blijenberg BG; Schröder FH
    Urology; 1995 Dec; 46(6):773-8. PubMed ID: 7502414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density.
    Bangma CH; Kranse R; Blijenberg BG; Schröder FH
    Urology; 1995 Dec; 46(6):779-84. PubMed ID: 7502415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening.
    Reissigl A; Klocker H; Pointner J; Fink K; Horninger W; Ennemoser O; Strasser H; Colleselli K; Höltl L; Bartsch G
    Urology; 1996 Dec; 48(6A Suppl):62-6. PubMed ID: 8973702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.
    Roehrborn CG; Gregory A; McConnell JD; Sagalowsky AI; Wians FH
    Urology; 1996 Dec; 48(6A Suppl):23-32. PubMed ID: 8973696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL.
    Törnblom M; Norming U; Adolfsson J; Becker C; Abrahamsson PA; Lilja H; Gustafsson O
    Urology; 1999 May; 53(5):945-50. PubMed ID: 10223488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population.
    Bangma CH; Rietbergen JB; Kranse R; Blijenberg BG; Petterson K; Schröder FH
    J Urol; 1997 Jun; 157(6):2191-6. PubMed ID: 9146612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma.
    Letran JL; Blase AB; Loberiza FR; Meyer GE; Ransom SD; Brawer MK
    J Urol; 1998 Aug; 160(2):426-9. PubMed ID: 9679891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
    Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
    Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma.
    Thakur V; Singh PP; Talwar M; Mukherjee U
    Dis Markers; 2003-2004; 19(6):287-92. PubMed ID: 15258330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normal range prostate-specific antigen versus age-specific prostate-specific antigen in screening prostate adenocarcinoma.
    el-Galley RE; Petros JA; Sanders WH; Keane TE; Galloway NT; Cooner WH; Graham SD
    Urology; 1995 Aug; 46(2):200-4. PubMed ID: 7542822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic significance of prostate-specific antigen velocity at intermediate PSA serum levels in relation to the standard deviation of different test systems.
    Manseck A; Pilarsky C; Froschermaier S; Menschikowski M; Wirth MP
    Urol Int; 1998; 60(1):25-7. PubMed ID: 9519417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cutoff level of free/total prostate specific antigen (f/t PSA) ratios in the diagnosis of prostate cancer: a validation study on a Turkish patient population in different age categories.
    Erol B; Gulpinar MT; Bozdogan G; Ozkanli S; Onem K; Mungan G; Bektas S; Tokgoz H; Akduman B; Mungan A
    Kaohsiung J Med Sci; 2014 Nov; 30(11):545-50. PubMed ID: 25458043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves.
    Catalona WJ; Richie JP; deKernion JB; Ahmann FR; Ratliff TL; Dalkin BL; Kavoussi LR; MacFarlane MT; Southwick PC
    J Urol; 1994 Dec; 152(6 Pt 1):2031-6. PubMed ID: 7525994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of free prostate specific antigen serum level and its related parameters in the diagnosis of prostate cancer.
    Haroun AA; Hadidy AS; Awwad ZM; Nimri CF; Mahafza WS; Tarawneh ES
    Saudi J Kidney Dis Transpl; 2011 Mar; 22(2):291-7. PubMed ID: 21422628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer.
    Okihara K; Cheli CD; Partin AW; Fritche HA; Chan DW; Sokoll LJ; Brawer MK; Schwartz MK; Vessella RL; Loughlin KR; Johnston DA; Babaian RJ
    J Urol; 2002 May; 167(5):2017-23; discussion 2023-4. PubMed ID: 11956430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of free prostate-specific antigen (Hybritech Tandem-R) in symptomatic patients consulting the urologist.
    Hofer C; Sauerstein P; Wolter C; Scholz M; Hartung R; Breul J
    Urol Int; 2000; 64(1):18-23. PubMed ID: 10782027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
    Catalona WJ; Smith DS; Ornstein DK
    JAMA; 1997 May; 277(18):1452-5. PubMed ID: 9145717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
    Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
    Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.